STAAR Surgical (NASDAQ:STAA) Major Shareholder Acquires $598,122.24 in Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. bought 34,296 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was purchased at an average cost of $17.44 per share, with a total value of $598,122.24. Following the acquisition, the insider now directly owns 12,319,691 shares in the company, valued at $214,855,411.04. This trade represents a 0.28 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, March 20th, Broadwood Partners, L.P. acquired 108,720 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.96 per share, with a total value of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. purchased 93,124 shares of STAAR Surgical stock. The stock was bought at an average price of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. bought 249,503 shares of STAAR Surgical stock. The stock was purchased at an average cost of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. purchased 259,316 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. bought 36,532 shares of STAAR Surgical stock. The stock was acquired at an average cost of $15.49 per share, with a total value of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The stock was bought at an average price of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. bought 8,221 shares of STAAR Surgical stock. The stock was purchased at an average cost of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. bought 21,155 shares of STAAR Surgical stock. The shares were acquired at an average price of $21.46 per share, with a total value of $453,986.30.

STAAR Surgical Trading Down 1.7 %

Shares of STAA stock traded down $0.31 during trading hours on Tuesday, reaching $17.46. 621,690 shares of the company’s stock were exchanged, compared to its average volume of 765,949. STAAR Surgical has a fifty-two week low of $13.50 and a fifty-two week high of $52.68. The stock’s 50 day moving average is $19.77 and its 200-day moving average is $25.52. The company has a market cap of $861.21 million, a price-to-earnings ratio of -42.59 and a beta of 0.66.

Wall Street Analysts Forecast Growth

STAA has been the subject of a number of research analyst reports. Mizuho lowered shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $45.00 to $17.00 in a report on Wednesday, February 12th. StockNews.com cut STAAR Surgical from a “hold” rating to a “sell” rating in a research note on Thursday, February 13th. BTIG Research lowered STAAR Surgical from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 12th. Canaccord Genuity Group dropped their price target on STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a research report on Thursday, February 13th. Finally, Piper Sandler cut their price target on STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, STAAR Surgical presently has an average rating of “Hold” and a consensus target price of $25.29.

Hedge Funds Weigh In On STAAR Surgical

Hedge funds and other institutional investors have recently bought and sold shares of the business. Quarry LP acquired a new stake in STAAR Surgical during the 3rd quarter valued at approximately $50,000. Quest Partners LLC acquired a new stake in STAAR Surgical during the 3rd quarter worth about $128,000. KLP Kapitalforvaltning AS purchased a new position in shares of STAAR Surgical during the 4th quarter valued at about $180,000. Larson Financial Group LLC lifted its holdings in shares of STAAR Surgical by 78.3% in the 3rd quarter. Larson Financial Group LLC now owns 4,863 shares of the medical instruments supplier’s stock valued at $181,000 after buying an additional 2,135 shares during the period. Finally, Bridgefront Capital LLC boosted its stake in shares of STAAR Surgical by 27.2% in the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock worth $262,000 after buying an additional 2,306 shares during the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.